

# Regioselective combination of 1,3-dinucleophiles such as 2-mercaptobenzimidazole, 5-mercapto-3-phenyltriazole and potassium thiocyanate with 2,2-dicyanooxiranes

Mohammad Seifi and Hassan Sheibani\*

*Department of Chemistry, Shahid Bahonar University of Kerman, Kerman 76169, Iran*

*E-mail: [hsheibani@mail.uk.ac.ir](mailto:hsheibani@mail.uk.ac.ir)*

DOI: <http://dx.doi.org/10.3998/ark.5550190.p008.002>

---

## Abstract

A group of heterocyclic compounds of condensed [1,3]thiazole with benzimidazole or triazole derivatives were obtained by the regioselective reactions of the 2,2-dicyanooxiranes with 1*H*-1,3-benzimidazol-2-thiol or 5-phenyl-4*H*-1,2,4-triazol-3-thiol respectively in good to excellent yields. Also, we performed a reaction between 2,2-oxiranedicarbonitrile reagents and potassium thiocyanate in acetic anhydride at room temperature and isolated 2-acetylmino-1,3-oxathiole derivatives.

**Keywords:** 2,2-Dicyanooxiranes, 1*H*-1,3-benzimidazol-2-thiols, 5-phenyl-4*H*-1,2,4-triazol-3-thiols, potassium thiocyanate

---

## Introduction

The design, synthesis and property of novel thiazole derivatives as a class of the most important heterocyclic compounds have been paid extensive and continuous attention in the fields of industry, agriculture and pharmacy.<sup>1,2</sup> Many synthetic small molecules from different groups of heterocycles with influence on carcinogenesis have been reported and several of them are currently in clinical trials.<sup>3</sup>


Thiazolone nuclei fused to heterocyclic systems represent a very important class of compounds used mainly as intermediates for the preparation of bioactive compounds. For example, 2-arylidene-[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-ones were found antibacterial agents,<sup>4</sup> inhibitors of ubiquitin ligase<sup>5</sup> and other enzymes, and they may be used for the treatment of viral and inflammatory diseases, neurological disorders and cancer. In addition, some isosteric thiazolo[3,4-*a*]benzimidazoles inhibit enteroviruses<sup>6</sup> and tumors.<sup>7</sup> The synthesis of such compounds has been the subject of several reviews which demonstrate the high importance of this class of compounds.<sup>8-13</sup> Considering the importance of these compounds, many methods for

the synthesis of these derivatives have been reported successively. The conventional synthesis involves the nucleophilic addition of 1,3-dinucleophiles with 2,2-dicyanooxirane, alkyl  $\alpha$ -haloacetate or  $\alpha$ -haloketone derivatives.<sup>14</sup> 2,2-Dicyanooxiranes and their  $\alpha$ -haloketone derivatives are known as very effective bielelectrophile reagents in the synthesis of a large variety of heterocyclic compounds of pharmaceutical interest such as thiazoles,<sup>15</sup> dithioles,<sup>16</sup> imidazoles,<sup>17</sup> 1,3-oxathioles<sup>18</sup> and condensed imidazolo and thiazolo derivatives,<sup>19</sup> because of their multifunctional structure. In general, nucleophilic reagents can react with these compounds regioselectively: they can attack the oxirane ring, cyano functional group to give either ring opened products, new functionalised oxiranes or different heterocycles. In our continuing interest in the synthesis of heterocycles containing nitrogen and sulfur atoms,<sup>20-22</sup> we decided to investigate the condensation reaction of 1,3-dinucleophiles with 2,2-dicyanooxiranes, which is extended to the formation of 1,3-thiazolone derivatives.

So in this paper, we describe an investigation of the condensation of potassium thiocyanate with 2,2-dicyanooxiranes which released to 1,3-oxathiole derivatives. These compounds are established in a variety of useful heterocyclic derivatives applied as biologically active compounds and pharmaceutical products.<sup>23, 24</sup>


## Results and Discussion

To study the regioselectivity of 1,3-dinucleophiles such as 1*H*-1,3-benzimidazol-2-thiol and 5-phenyl-4*H*-1,2,4-triazol-3-thiol with 2,2-dicyanooxiranes, we have investigated the nucleophilic reaction of 1*H*-1,3-benzimidazol-2-thiol **2** with 2,2-dicyanooxiranes **1a-d** to prepare of 2-arylidene [1,3]thiazolo[3,2,*a*]benzimidazol-3(2*H*)-one (**3a-d**) derivatives in mild reaction conditions in good to excellent yields (Scheme 1).




Scheme 1

Encouraged by these results, we have extended these reactions by nucleophilic addition of 5-substituted 5-phenyl-4*H*-1,2,4-triazol-3-thiol **4** on 2,2-dicyanooxiranes **1b** and **1d** to synthesis of 5-substituted thiazolo[3,2-*b*][1,2,4]triazol-6-ones **5a-b** in good yields (Scheme 2).




### Scheme 2

In these protocols (Scheme 1 and 2) we have investigated reactions of 2,2-dicyanooxiranes **1**, which have three electron-deficient centers, with 1,3-dinucleophile such as 1*H*-1,3-benzimidazol-2-thiol **2** and 5-phenyl-4*H*-1,2,4-triazol-3-thiol **4** which afforded 2-arylidene[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one **3a-d** and 5-substituted thiazolo[3,2-*b*][1,2,4]triazol-6-one **5a-b** derivatives, respectively. In these reactions 1,3-dinucleophiles act via regioselective on C<sub>β</sub> and C<sub>α</sub> of 2,2-dicyanooxiranes **1** which have three electron deficient centers. These processes are highly regioselective, and compounds **3** and **5** results from the initial attack of the nucleophilic sulfur atom of compounds **2** and **4** on C<sub>β</sub> of 2,2-dicyanooxiranes **1** followed by ring-opening to form cyanohydrin intermediate and then cyanoformyl intermediate **I**, **II** was formed by losing of cyano group. The last step is along with intramolecular nucleophilic addition of nitrogen on carbonyl group of cyanoformyl intermediate **I**, **II** and followed by the elimination of HCN to form only one product (Scheme 3).



### Scheme 3

Encouraged by these results, we performed the reaction of 2,2-dicyanooxiranes (**1a**, **1b** and **1d**) with potassium thiocyanate **6** in acetic anhydride **7** at room temperature and isolated 2-acetylimino-1,3-oxathiole derivatives **8a-c**. The reaction presumably proceeds through thiocyanate attack on C<sub>β</sub> of 2,2-dicyanooxiranes **1** followed by ring-opening to form cyanhydrin intermediate **A**. The intramolecular nucleophilic addition of oxygen on carbon of nitrile intermediate **A** leads to the formation of intermediate **B** which is trapped by acetic anhydride to yield intermediate **C**. The last step is along with elimination of HCN from intermediate (**C**) and then formation of 1,3-oxathioles **8a-c** (Scheme 4).



#### Scheme 4

The structure of compounds **3a-d**, **5a**, **5b** and **8a-c** were determined on the basis of their elemental analyses, mass spectrum, <sup>1</sup>H and <sup>13</sup>C NMR and IR spectroscopic data. Only one product was obtained in each case. The <sup>1</sup>H NMR spectrum of **3a** indicated two kinds of protons along with one signal at 6.40 ppm attributed to one proton of C<sub>2</sub>. The aryl protons appeared at δ 8.82-7.39 ppm (9H, m). The <sup>1</sup>H decoupled <sup>13</sup>C NMR spectrum of **3a** was measured in DMSO-*d*<sub>6</sub> and it is in accord with the proposed structure. The <sup>13</sup>C NMR of compound **3a** showed two signals at δ 153.84 and 144.75 ppm which are due to the carbonyl and imine carbons respectively. The ten aromatic carbons appeared at δ 142.92-117.76 ppm. These signals along with an upfield shift of aliphatic carbon at δ 50.10 ppm which was identified as aliphatic carbon (C<sub>2</sub>). Also the structure of compound **8a** was established on the basis of spectral data, which IR

spectrum of this compound showed the presence of CN at region  $2225\text{cm}^{-1}$  and sharp bands at  $1662$  and  $1601\text{ cm}^{-1}$ , which are due to carbonyl of amide (C=O) and imine (C=N) groups respectively. The  $^1\text{H}$  NMR spectrum of **8a** indicated two kinds of proton signals with one at  $\delta$  2.66 (s, 3H,  $\text{CH}_3$ ) ppm was identified as acetyl group. The five protons of phenyl group appeared at  $\delta$  7.77-7.64 ppm. The  $^{13}\text{C}$  NMR of compound **8a** showed two signals at  $\delta$  181.95 and 174.06 ppm which are due to the carbonyl of amide (C=O) and imine (C=N) groups respectively. The oxygen and cyano groups adjacent to double bond strongly polarize the double bond system. The  $\alpha$ -carbon ( $\text{C}_5$ ) and  $\beta$ -carbon ( $\text{C}_4$ ) of these substituents appear at  $\delta$  138.41 and 114.67 ppm respectively. The aromatic carbons along with nitril carbon appeared at  $\delta$  131.79, 129.82, 127.64, 126.34 and 110.39 (CN) ppm respectively. These signals along with the upfield shift of aliphatic carbon at  $\delta$  27.08 ppm which was identified as acetyl group.

## Conclusions

We have developed a simple and efficient method for the synthesis of heterocyclic compounds which condensed [1,3]thiazole with benzimidazole or triazole derivatives via reaction of 2,2-dicyanooxiranes with 1,3-dinucleophiles. We have investigated reaction of potassium thiocyanate with 2,2-dicyanooxiranes in acetic anhydride to synthesis of oxathiole derivatives. The advantage of these procedures reported here are: high selectivity, high purity of products and easy workup.

## Experimental Section

**General.** Melting points were measured on a Electrothermal Engineering LTD apparatus and are uncorrected. IR spectra were measured on a Mattson 1000 FT-IR spectrometer. The proton and carbon NMR spectra were recorded with a BRUKER DRX-400 AVANCE spectrometer at 400 and 100 MHz, respectively. Mass spectra were recorded on a MS-QP2000A Shimadzu mass spectrometer operating at an ionization potential of 70 eV. Elemental analyses were performed using a Heracus CHN-O-Rapid analyzer. 2,2-dicyanooxiranes **1a-d** was prepared according to a literature procedure.<sup>25</sup>

**Procedure for the preparation of 2-arylidene [1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one (3a-d) and 5-substituted thiazolo[3,2-*b*][1,2,4]triazol-6-ones (5a-b).** A mixture of 2,2-dicyanooxiranes **1a-d** (2 mmol) and 1*H*-benzo[*d*]imidazole-2-thiol **2** or 5-mercapto-3-phenyl-*s*-triazole **4** (2 mmol) in  $\text{CH}_3\text{CN}$  (20 mL) was stirred for 7 hour (the progress of the reaction being monitored by TLC and was used hexane/ethyl acetate as an eluent). When the reaction was completed as indicated by TLC, the crude product **3a-3d** and **5a, 5b** was precipitated from the reaction mixture, and the solid was filtered and recrystallized with hexane/ethyl acetate to get pure product.

**2-Phenyl[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one (3a).** White crystals; yield: 90%. mp 190-192 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1742 (C=O), 1603 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 8.81 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.71 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.67-7.39 (m, 7H, Ar), 6.40 (s, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 153.84 (C=O), 144.75 (C=N), 142.92, 133.21, 132.69, 132.38, 129.45, 129.04, 128.93, 124.63, 122.87, 117.76, 50.10 (C<sub>2</sub>). MS (*m/z*): 266 (M<sup>+</sup>) (98), 237 (80), 205 (20), 150 (15), 121 (100), 90 (78), 77 (40). Anal. calcd. for C<sub>15</sub>H<sub>10</sub>N<sub>2</sub>OS: C, 67.65; H, 3.78; N, 10.52%. Found: C, 67.42; H, 3.66; N, 10.18%.

**2-(4-Chlorophenyl)[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one (3b).** White crystals; yield: 93%. mp 136-139 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1726 (C=O), 1609 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 7.87 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.66 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.62 (d, 2H,  $^3J_{\text{H-H}} = 8.8$  Hz, CH), 7.50 (d, 2H,  $^3J_{\text{H-H}} = 8.8$  Hz, CH), 7.42 (t, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.35 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 6.32 (s, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 166.83 (C=O), 156.88 (C=N), 149.42, 133.61, 133.44, 131.17, 128.72, 128.02, 125.77, 123.74, 123.35, 118.70, 67.32 (C<sub>2</sub>). MS (*m/z*): 300 (M<sup>+</sup>) (100), 271 (70), 237 (50), 156 (80), 124 (20), 89 (73), 63 (40). Anal. calcd. for C<sub>15</sub>H<sub>9</sub>ClN<sub>2</sub>OS: C, 59.90; H, 3.02; N, 9.31%. Found: C, 59.83; H, 2.88; N, 9.01%.

**2-(4-Nitrophenyl)[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one (3c).** White crystals; yield: 94%. mp 193-196 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1750 (C=O), 1609 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 8.49 (d, 2H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.72 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.50-7.26 (m, 5H, Ar), 5.79 (s, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 165.83 (C=O), 153.20 (C=N), 150.3, 145.4, 140.01, 138.5, 129.73, 126.56, 124.55, 124.49, 119.51, 128.9, 57.61 (C<sub>2</sub>). MS (*m/z*): 311 (M<sup>+</sup>) (100), 282 (20), 265 (15), 236 (40), 167 (98), 151 (20), 145 (50), 121 (30), 109 (20), 90 (77), 77 (80), 63 (88). Anal. calcd. for C<sub>15</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>S: C, 57.87; H, 2.91; N, 13.50%. Found: C, 57.69; H, 2.85; N, 13.21%.

**2-(2,5-Dimethoxyphenyl)[1,3]thiazolo[3,2-*a*]benzimidazol-3(2*H*)-one (3d).** Yellow crystals; yield: 90%. mp 140-143 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1748 (C=O), 1611 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 7.81 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.49 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.31-7.12 (m, 2H, CH), 7.05 (s, 1H, CH), 7.02 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 6.88 (d, 1H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 6.01 (s, 1H), 3.65, 3.48 (s, 6H, 2OCH<sub>3</sub>).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 167.91 (C=O), 154.70 (C=N), 152.59, 150.56, 126.40, 124.75, 124.38, 123.38, 119.61, 117.79, 116.30, 56.88, 56.09 (2OCH<sub>3</sub>) 57.61 (C<sub>2</sub>). MS (*m/z*): 326 (M<sup>+</sup>) (100), 311 (85), 267 (20), 178 (15), 163 (50), 149 (60), 135 (20), 121 (40), 107 (12), 91 (30), 77 (43), 63 (35). Anal. calcd. for C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S: C, 62.56; H, 4.32; N, 8.58%. Found: C, 62.44; H, 4.28; N, 8.31%.

**5-(4-Chlorophenyl)-2-phenylthiazolo[3,2-*b*][1,2,4]triazol-6(5*H*)-one (5a).** White crystals; yield: 90%. mp 152-155 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1744 (C=O), 1692, 1611 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 8.13-8.11 (m, 2H, Ar), 7.64 (d, 2H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 7.57-7.53 (m, 3H, Ar), 7.50 (d, 2H,  $^3J_{\text{H-H}} = 8$  Hz, CH), 6.41 (s, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 169.73 (C=O), 165.03, 163.96 (C=N), 134.00, 132.56, 131.35, 131.27, 129.15, 129.04, 128.97, 126.90, 58.17 (C<sub>5</sub>). MS (*m/z*): 327 (M<sup>+</sup>) (80), 301 (12), 281 (12), 264 (55), 177 (20), 152 (60), 125 (40), 103 (100), 89 (85), 77 (30). Anal. calcd. for C<sub>16</sub>H<sub>10</sub>ClN<sub>3</sub>OS: C, 58.63; H, 3.07; N, 12.28%. Found: C, 58.44; H, 2.98; N, 11.97%.

**5-(2,5-Dimethoxyphenyl)-2-phenylthiazolo[3,2-*b*][1,2,4]triazol-6(5*H*)-one (5b).** Orange crystals; yield: 94%. mp: 204-206 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 1754 (C=O), 1606 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 8.13 (d, 2H,  $^3J_{\text{H-H}}=8\text{Hz}$ , CH), 7.70-7.66 (m, 3H, Ar), 7.20 (s, 1H, CH), 7.05-7.00 (m, 2H, CH), 6.31 (s, 1H), 3.76, 3.67 (s, 6H, 2OCH<sub>3</sub>).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 169.09 (C=O), 164.73, 164.32 (C=N), 153.08, 151.17, 131.19, 129.10, 129.05, 126.88, 122.58, 117.28, 115.78, 56.45, 55.84 (2OCH<sub>3</sub>), 55.67 (C<sub>5</sub>). MS (*m/z*): 353 (M<sup>+</sup>) (12), 294 (7), 178 (30), 163 (95), 147 (20), 135 (23), 121 (15), 103 (100), 92 (18), 77 (28). Anal. calcd. for C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S: C, 61.18; H, 4.28; N, 11.89%. Found: C, 60.95; H, 4.15; N, 11.60%.

**Procedure for preparation of 2-acetylimino-1,3-oxathiole derivatives 8a-c.** A mixture of 2,2-dicyanooxiranes **1a-d** (2 mmol) and KSCN (2 mmol) was dissolved in 10 ml of acetic anhydride and stirred at room temperature for 3 h. The product precipitated from the reaction mixture and was collected by filtration. It was recrystallized from EtOH.

**(5*E*)-*N*-(5-Cyano-4-phenyl)-1,3-oxathiol-2-ylidene)acetamide (8a).** Brown crystals; yield: 90%. mp 97-99 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 2225 (CN), 1662 (C=O), 1601 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 7.77-7.74 (m, 3H, Ar), 7.64 (d, 2H,  $^3J_{\text{H-H}} = 8\text{ Hz}$ , CH), 2.66 (s, 3H, CH<sub>3</sub>).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 181.95 (C=O), 174.06 (C=N), 138.41 (C<sub>5</sub>), 131.79, 129.82, 127.64, 126.34, 114.67 (C<sub>4</sub>), 110.39 (CN), 27.08 (CH<sub>3</sub>). MS (*m/z*): 244 (M<sup>+</sup>) (7), 193 (8), 168 (15), 135(18), 121 (100), 107 (10), 89 (45), 77 (85). Anal. calcd. for C<sub>12</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>S: C, 59.00; H, 3.30; N, 11.47%. Found: C, 58.79; H, 3.21; N, 11.12%.

**(5*E*)-*N*-(4-(4-Chlorophenyl)-5-cyano-1,3-oxathiol-2-ylidene)acetamide (8b).** Yellow crystals; yield: 95%. mp 117-120 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 2229 (CN), 1666 (C=O), 1599 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 7.77 (d, 2H,  $^3J_{\text{H-H}} = 8\text{ Hz}$ , CH), 7.72 (d, 2H,  $^3J_{\text{H-H}} = 8\text{ Hz}$ , CH), 2.36 (s, 3H, CH<sub>3</sub>).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 182.66 (C=O), 163.37 (C=N), 149.82 (C<sub>5</sub>), 136.97, 136.46, 129.90, 128.63, 124.29 (C<sub>4</sub>), 110.22 (CN), 26.70 (CH<sub>3</sub>). MS (*m/z*): 278 (M<sup>+</sup>) (90), 237 (8), 209 (8), 180(10), 155 (100), 114 (80), 93 (40), 70 (65). Anal. calcd. for C<sub>12</sub>H<sub>7</sub>ClN<sub>2</sub>O<sub>2</sub>S: C, 51.71; H, 2.53; N, 10.05%. Found: C, 51.48; H, 2.27; N, 9.71%.

**(5*E*)-*N*-(5-Cyano-4-(2,5-dimethoxyphenyl)-1,3-oxathiol-2-ylidene)acetamide (8c).** Yellow crystals; yield: 92%. mp 186-189 °C. IR (KBr,  $\nu_{\max}/\text{cm}^{-1}$ ): 2229 (CN), 1656 (C=O), 1609 (C=N).  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): 7.26-7.20 (m, 3H, Ar), 3.86, 3.77 (s, 6H, 2OCH<sub>3</sub>), 2 (s, 3H, CH<sub>3</sub>).  $^{13}\text{C}$  NMR (100 MHz, DMSO-*d*<sub>6</sub>): 181.95 (C=O), 174.36 (C=N), 153.14 (C<sub>5</sub>), 152.77, 150.62, 118.68, 115.42, 114.52, 113.85, 113.40 (C<sub>4</sub>), 110.323 (CN), 56.34, 55.70 (2OCH<sub>3</sub>), 26.89 (CH<sub>3</sub>). MS (*m/z*): 304 (M<sup>+</sup>) (10), 262 (30), 235 (25), 181 (100), 149 (90), 133 (40), 121 (70), 107 (18), 95 (20), 77 (8). Anal. calcd. for C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>S: C, 55.52; H, 3.97; N, 9.21%. Found: C, 55.39; H, 3.89; N, 8.94%.

## Acknowledgements

The authors express appreciation to the Shahid Bahonar University of Kerman Faculty Research Committee for its support of this investigation.

## References

1. Ares, J. J. *Synth. Commun.* **1991**, *21*, 625.  
<http://dx.doi.org/10.1080/00397919108020829>
2. Fang, D.; Wei, H.; Luyt, A. S. *Chin. Chem. Lett.* **2011**, *22*, 109.  
<http://dx.doi.org/10.1016/j.cclet.2010.09.019>
3. Eckhardt, S. *Curr. Med. Chem. Anticancer Agents* **2002**, *2*, 419.  
<http://dx.doi.org/10.2174/1568011024606389>  
PMid:12678741
4. Allanson, N. M.; Leslie, B. W.; Thomson, S. Pat. UK. Application 2002, *12*, 31.
5. Alroy, I.; Tuvia, Sh.; Reiss, Levi-Hacham, YO. Pat. USA. Application 2007, *18*, 1.
6. Leyssen, P.; De Clercq, E.; Neyts, J. *Antivir. Res.* **2008**, *78*, 9.  
<http://dx.doi.org/10.1016/j.antiviral.2008.01.004>  
PMid:18313769
7. Monforte, P.; Musumeci, L.; Rao, A.; Zappala, M.; Monforte, A. M. *Arch. Pharm.* **2001**, *334*, 203.
8. Franis, J. E.; Cashi, W.; Psychoyos, D. S.; Wenk, G. P.; Friedmann, R. C.; Atkins, C.; Warren, W.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. *J. Med. Chem.* **1988**, *31*, 1014.  
<http://dx.doi.org/10.1021/jm00400a022>
9. Bentabed-Ababsa, G.; Hamza-Reguig, S.; Derdour, A.; Domingo, L. R.; Saez, J. A.; Roisnel, T.; Dorcet, V.; Nassar, V.; Mongin, F. *Org. Bio. Chem.* **2012**, *10*, 8434.  
<http://dx.doi.org/10.1039/c2ob26442k>  
PMid:23011385
10. Ghailane, T.; Saadouni, M.; Boukhris, S.; Habbadi, N.; Hassikou, A.; Kerbal, A.; Garrigues, B.; Souizi, A. *Heterocycles* **2011**, *83*, 357.  
<http://dx.doi.org/10.3987/COM-10-12096>
11. Bentabed-Ababsa, G.; Derdour, A.; Roisnel, T.; Saez, J. A.; Perez P.; Chamorro E.; Domingo, L. R.; Mongin, F. *J. Org. Chem.* **2009**, *74*, 2120.  
<http://dx.doi.org/10.1021/jo8027104>  
PMid:19199802
12. Bentabed-Ababsa, G.; Derdour, A.; Roisnel, T.; Saez, J. A.; Domingo, L. R.; Mongin, F. *Org. Bio. Chem.* **2008**, *6*, 3144.  
<http://dx.doi.org/10.1039/b804856h>  
PMid:18698474
13. Kim, Y. C.; Ji, X. D.; Jacobson, K. A. *J. Med. Chem.* **1996**, *39*, 4142.  
<http://dx.doi.org/10.1021/jm960482i>  
PMid:8863790
14. Robert, A.; Baudy-Floc'h, M.; Le Grel, P.; Foucaud, A. *Trends in Org. Chem.* **1995**, *5*, 37.



15. Majcen-Le Maréchal, A.; Robert, A.; Leban, I. *Tetrahedron* **1990**, *46*, 453.  
[http://dx.doi.org/10.1016/S0040-4020\(01\)85429-6](http://dx.doi.org/10.1016/S0040-4020(01)85429-6)
16. Souizi, A.; Robert, A. *C. R. Acad. Sci., Paris Ser.* **1982**, *295*, 571.
17. Guillemet, M.; Robert, A.; Baudy-Floc'h, M. *Tetrahedron Lett.* **1995**, *36*, 547.  
[http://dx.doi.org/10.1016/0040-4039\(94\)02337-B](http://dx.doi.org/10.1016/0040-4039(94)02337-B)
18. Majcen-Le Maréchal, A.; Robert, A.; Leban, I. *J. Chem. Soc., Perkin Trans.* **1993**, *1*, 351.
19. Majcen-Le., Maréchal, A.; Le Grel, P.; Robert, A.; Biškup, J.; Ferk, V.; Toplak, R. *Arkivoc* **2001**, (v), 119.
20. Cantillo, D.; Sheibani, H.; Kappe, C. O. *J. Org. Chem.* **2012**, *77*, 2463.  
<http://dx.doi.org/10.1021/jo3001645>  
PMid:22321044
21. Sheibani, H.; Hassani, F. *J. Heterocyclic. Chem.* **2011**, *48*, 915.  
<http://dx.doi.org/10.1002/jhet.640>
22. Sheibani, H.; Amrollahi, M. A.; Esfandiarpour, Z. *Mol Divers.* **2010**, *14*, 277.  
<http://dx.doi.org/10.1007/s11030-009-9165-5>  
PMid:19543800
23. Konieczny, M. T.; Konieczny, W.; Sabisz, M.; Skladanowski, A.; Wakiec, R.; Augustynowicz -Kopec, E.; Zwolska, Z. *Chem. Pharm. Bull.* **2007**, *55*, 817.
24. Aizawa, Y.; Kanai, T.; Hasegawa, K.; Yamaguchi, T.; Iizuka, T.; Iwaoka, T.; Yoshioka, T. *J. Med. Chem.* **1990**, *33*, 1491.  
<http://dx.doi.org/10.1021/jm00167a032>
25. Volmajer, J.; Toplak, R.; Bittner, S.; Marechal, A. M. L. *Arkivoc* **2003**, (xiv), 49.  
<http://dx.doi.org/10.3998/ark.5550190.0004.e06>